All PlansCoverageLow impact
Systems Pathology in Prostate Cancer
Blue Cross & Blue Shield of Mississippi·Urology, Oncology, Pathology·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy confirms that Systems Pathology tests for prostate cancer (including cellular and biologic features for predicting cancer recurrence) remain classified as investigational and not covered. While this appears to be a recent policy publication, the actual coverage determination has not changed from previous versions.
Action Required
No immediate action required. Continue to deny or obtain patient consent for self-pay when providers order Systems Pathology tests for prostate cancer using the listed CPT codes, as these remain investigational and non-covered services.